North America Lung Cancer Therapeutics Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2028.
Market Analysis and Insights of North America Lung Cancer Therapeutics Market
Data Bridge Market Research analyses that the lung cancer therapeutics market will exhibit a CAGR of around 6.1% for the forecast period of 2021-2028. Rising prevalence of cancer and other chronic disorders, increased focus on research and development proficiencies in regards to medical devices and on the adoption of advanced healthcare technologies, growing fondness for smoking especially among the youngsters and rising expenditure for the development of healthcare infrastructure development especially in the developing economies are the major factors attributable to the growth of lung cancer therapeutics market.
Also known as lung carcinoma, lung cancer refers to the abnormal growth of cancerous cells in the lungs and is also known as lung carcinoma. Lung cancer decreases the efficiency of lungs and disrupts its efficient functioning. The major causes of lung cancer are smoking pipes, cigarette cigar and asbestos exposure and common symptoms include cough, chest pain, weight loss, and shortness of breath.
Upsurge in the demand for target mode of therapies is one of the major factors fostering the growth of the market. Growth in the funding in the field of research and development of new drugs is another market growth determinant. Rising industrialization, growth in the level of air pollution, surging consumption of tobacco, rise in the prevalence of unhealthy lifestyles and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.
However, improper and unfavourable reimbursement scenario in the developing and underdeveloped economies will derail the market growth rate. Also, high costs associated with research and development proficiencies, availability of generic drugs and poor cancer diagnostic facilities in the underdeveloped economies will further pose challenges for the market. Dearth of skilled professionals in the backward economies and high cost and the adverse effect of radiation and chemotherapies will also hamper the market growth rate.
This lung cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
North America Lung Cancer Therapeutics Market Scope and Market Size
The lung cancer therapeutics market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of cancer type, the lung cancer therapeutics market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumours, pulmonary neuroendocrine tumours and mediastinal tumours.
- On the basis of molecule type, the lung cancer therapeutics market is segmented into small molecules and biologics.
- On the drug class, the lung cancer therapeutics market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors and others.
- On the basis of treatment type, the lung cancer therapeutics market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs.
- On the basis of therapy type, the lung cancer therapeutics market is segmented into single drug therapy and combination therapy.
- On the basis of end user, the lung cancer therapeutics market is segmented into hospitals, specialty clinics, homecare and others.
- On the basis of distribution channel, the lung cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, online and others.
North America Lung Cancer Therapeutics Market Country Level Analysis
The lung cancer therapeutics market is analysed and market size insights and trends are provided by country, drug type, product, form, application and end user as referenced above.
The countries covered in the lung cancer therapeutics market report are U.S., Canada and Mexico.
U.S. in North America dominates the lung cancer therapeutics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increasing funding for research and development activities, ever-rising geriatric population, prevalence of advanced diagnostic technologies, surging consumption of tobacco and ever-increasing instances of lung cancer.
The country section of the lung cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The lung cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer therapeutics market. The data is available for historic period 2010 to 2019.
Competitive Landscape and North America Lung Cancer Therapeutics Market Share Analysis
The lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to lung cancer therapeutics market.
The major players covered in the lung cancer therapeutics market report are Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, Amgem Inc., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., among other. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-